Aviso: para depositar documentos, por favor, inicia sesión e identifícate con tu cuenta de correo institucional de la UCM con el botón MI CUENTA UCM. No emplees la opción AUTENTICACIÓN CON CONTRASEÑA
 

Comparison of 2 medium cutoff dialyzers versus on‐line hemodiafiltration regarding depurative ability and albumin loss: An uncontrolled clinical research

Citation

Martínez‐Miguel, Patricia, et al. «Comparison of 2 Medium Cutoff Dialyzers versus On‐line Hemodiafiltration Regarding Depurative Ability and Albumin Loss: An Uncontrolled Clinical Research». Artificial Organs, vol. 47, n.o 3, marzo de 2023, pp. 589-94. https://doi.org/10.1111/aor.14466.

Abstract

Abstract Background Hemodialysis (HD) techniques that best remove molecules in the middle to high molecular weight range are on-line hemodiafiltration (OL-HDF) and HD with medium cut-off (MCO) membranes. The aim of this study was to compare efficacy and safety of OL-HDF with FxCordiax HDF 800™, with HD with 2 MCO dialyzers: Theranova 500® and the new Elisio 21HX™ dialyzer. Methods Fourteen patients following treatment with OL-HDF using FxCordiax HDF 800™ were randomized to receive a consecutive 1-week HD treatment with Theranova 500® and Elisio 21HX™.The reduction rate (RR) of differently sized molecules was compared, as well as the variation rate in molecules smaller than 1000, detected by nuclear magnetic resonance based chemometrics (metabolomics). Albumin loss in dialysate was quantified. Results Lower RRs were found for molecules around 20 000 with Elisio 21HX™ compared to OL- HDF (RR prolactin 58.5% versus 66.7%, p = 0.034; RR Kappa light chain 63.1% versus 71.8%, p = 0.010). Albumin loss per session was higher with Theranova 500® than with OL-HDF and with Elisio 21HX™ (2249.9 ± 714.1 mg, 815.2 ± 474.0 mg, 442.9 ± 135.9 mg, p < 0.001, respectively). Metabolomic studies suggested, by semi-quantitative analysis, a greater depurative capacity of OL-HDF, followed by Elisio 21HX™, and then Theranova 500®. Conclusions In this study, HD with Theranova 500® has proven to be very similar in efficacy to OL-HDF, although with a significantly higher albumin loss. HD with Elisio 21HX™ resulted in lower removal of molecules around 20 000 compared to OL-HDF, with no significant difference compared to Theranova 500®, and with less albumin loss than Theranova 500®.

Research Projects

Organizational Units

Journal Issue

Description

ACKNOWLEDGMENTS The Ethics Committee for Research involving medical products of the Hospital Universitario Príncipe de Asturias, at its meeting on 23 February 2021, and after evaluating the proposal by the sponsor regarding the specified study, considered issuing a FAVORABLE OPINION for the study to be carried out. FUNDING INFORMATION This work was partially financed by Nipro.

Unesco subjects

Keywords

Collections